

Drug-Eluting Stents in Angina

Bibliography of One Hundred Key Papers

selected by **William Wijns***, MD, PhD, FESC and **Marco Valgimigli†**, MD

*Cardiovascular Center Aalst - Aalst - BELGIUM - (e-mail: william.wijns@village.uu.net.be)

†Cardiovascular Institute - Arcispedale S. Anna - University of Ferrara - Ferrara - ITALY

-
- | | |
|--|--|
| Awata M, Kotani J, Uematsu M, et al. | <i>Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents.</i>
Circulation. 2007;116:910-916. |
| Brilakis ES, Banerjee S, Berger PB. | <i>Perioperative management of patients with coronary stents.</i>
J Am Coll Cardiol. 2007;49:2145-2150. Review. |
| Brunner-La Rocca HP, Kaiser C, Pfisterer M; BASKET Investigators. | <i>Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET).</i>
Eur Heart J. 2007;28:719-725. |
| Buonamici P, Marcucci R, Migliorini A, et al. | <i>Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.</i>
J Am Coll Cardiol. 2007;49:2312-2317. |
| Campo G, Valgimigli M, Gemmati D, et al. | <i>Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study.</i>
J Am Coll Cardiol. 2006;48:2178-2185. |
| Chen BX, Ma FY, Luo W, et al. | <i>Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography.</i>
Heart. 2008;94:566-570. |
| Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. | <i>Bare-metal stent restenosis is not a benign clinical entity.</i>
Am Heart J. 2006;151:1260-1264. |
| Chieffo A, Morici N, Maisano F, et al. | <i>Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience.</i>
Circulation. 2006;113:2542-2547. |
| Chieffo A, Park SJ, Valgimigli M, et al. | <i>Favorable long-term outcome after drug-eluting stent implantation in nonbifurcation lesions that involve unprotected left main coronary artery: a multicenter registry.</i>
Circulation. 2007;116:158-162. |
| Cosgrave J, Melzi G, Biondi-Zoccai GG, et al. | <i>Drug-eluting stent restenosis the pattern predicts the outcome.</i>
J Am Coll Cardiol. 2006;47:2399-2404. |
| Daemen J, Kukreja N, van Twisk PH, et al. | <i>Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam cardiology hospital registry.</i>
Am J Cardiol. 2008;101:1105-1111. |
-

Bibliography of One Hundred Key Papers

- Dibra A, Kastrati A, Mehilli J, et al; ISAR-DIABETES Study Investigators.** Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. *N Engl J Med.* 2005;353:663-670.
-
- Eisenberg MJ.** Drug-eluting stents: the price is not right. *Circulation.* 2006;114:1745-1754.
-
- Eisenstein EL, Anstrom KJ, Kong DF, et al.** Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. *JAMA.* 2007;297:159-168.
-
- Elezi S, Dibra A, Folkerts U, et al.** Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease. *J Am Coll Cardiol.* 2006;48:262-267.
-
- Elezi S, Dibra A, Mehilli J, et al.** Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. *J Am Coll Cardiol.* 2006;48:1304-1309.
-
- Fajadet J, Wijns W, Laarman GJ, et al; ENDEAVOR II Investigators.** Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. *Circulation.* 2006;114:798-806.
-
- Galløe AM, Thuesen L, Kelbaek H, et al; SORT OUT II Investigators.** Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. *JAMA.* 2008;299:409-416.
-
- Gerber R, Colombo A.** Does IVUS guidance of coronary interventions affect outcome? A prime example of the failure of randomized clinical trials. *Catheter Cardiovasc Interv.* 2008;71:646-654.
-
- Grines CL, Bonow RO, Casey DE Jr, et al; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians.** Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association with representation from the American College of Physicians. *J Am Coll Cardiol.* 2007;49:734-739.
-
- Hamon M, Biondi-Zoccai GG, Malagutti P, et al.** Diagnostic performance of multislice spiral computed tomography of coronary arteries as compared with conventional invasive coronary angiography: a meta-analysis. *J Am Coll Cardiol.* 2006;48:1896-1910.
-
- Hannan EL, Racz M, Holmes DR, et al.** Comparison of coronary artery stenting outcomes in the eras before and after the introduction of drug-eluting stents. *Circulation.* 2008;117:2071-2078.
-
- Hannan EL, Wu C, Walford G, et al.** Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. *N Engl J Med.* 2008;358:331-341.
-
- Holmes DR Jr, Kereiakes DJ, Laskey WK, et al.** Thrombosis and drug-eluting stents: an objective appraisal. *J Am Coll Cardiol.* 2007;50:109-118. Review.
-



-
- Holmes DR Jr, Teirstein P, Satler L, et al; SISR Investigators.** *Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial.* **JAMA.** 2006;295:1264-1273.
-
- Hong MK, Mintz GS, Lee CW, et al.** *Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up.* **Circulation.** 2006;113:414-419.
-
- Hwang CW, Levin AD, Jonas M, Li PH, Edelman ER.** *Thrombosis modulates arterial drug distribution for drug-eluting stents.* **Circulation.** 2005;111:1619-1626.
-
- Iakovou I, Schmidt T, Bonizzi E, Ge L, et al.** *Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.* **JAMA.** 2005;293:2126-2130.
-
- Jaffe R, Strauss BH.** *Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives.* **J Am Coll Cardiol.** 2007;50:119-127.
-
- Joner M, Finn AV, Farb A, et al.** *Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.* **J Am Coll Cardiol.** 2006;48:193-202.
-
- Kaiser C, Brunner-La Rocca HP, et al; BASKET Investigators.** *Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET).* **Lancet.** 2005;366:921-929. Erratum in: **Lancet.** 2005;366:2086.
-
- Kandzari DE, Leon MB, Popma JJ, et al; ENDEAVOR III Investigators.** *Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.* **J Am Coll Cardiol.** 2006;48:2440-2447.
-
- Kastrati A, Dibra A, Spaulding C, et al.** *Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction.* **Eur Heart J.** 2007;28:2706-2713.
-
- Kastrati A, Mehilli J, Pache J, et al.** *Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.* **N Engl J Med.** 2007;356:1030-1039.
-
- Kelbaek H, Terkelsen CJ, Helqvist S, et al.** *Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trial.* **J Am Coll Cardiol.** 2008;51:899-905.
-
- Kereiakes DJ, Wang H, Popma JJ, et al.** *Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials.* **J Am Coll Cardiol.** 2006;48:21-31.
-
- Kim YH, Ahn JM, Park DW, et al.** *EuroSCORE as a predictor of death and myocardial infarction after unprotected left main coronary stenting.* **Am J Cardiol.** 2006;98:1567-1570.
-

Bibliography of One Hundred Key Papers

- Kimura M, Mintz GS, Carlier S, et al.** *Outcome after acute incomplete sirolimus-eluting stent apposition as assessed by serial intravascular ultrasound.*
Am J Cardiol. 2006;98:436-442.
-
- Kimura M, Mintz GS, Weissman NJ, et al.** *Meta-analysis of the Effects of paclitaxel-eluting stents versus bare-metal stents on volumetric intravascular ultrasound in patients with versus without diabetes mellitus.*
Am J Cardiol. 2008;101:1263-1268.
-
- Krucoff MW, Kereiakes DJ, Petersen JL, et al; COSTAR II Investigators Group.** *A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.*
J Am Coll Cardiol. 2008;51:1543-1552.
-
- Laarman GJ, Suttorp MJ, Dirksen MT, et al.** *Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention.*
N Engl J Med. 2006;355:1105-1113.
-
- Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L; SCAAR Study Group.** *Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.*
N Engl J Med. 2007;356:1009-1019.
-
- Liistro F, Fineschi M, Angioli P, et al.** *Effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis: the TRUE (Tuscany Registry of Sirolimus for Unselected In-Stent Restenosis) Registry.*
J Am Coll Cardiol. 2006;48:270-275.
-
- Lotrionte M, Biondi-Zoccai GG, et al.** *Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention.*
Am J Cardiol. 2007;100:1199-1206. Review.
-
- Lüscher TF, Steffel J, Eberli FR, et al.** *Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications.*
Circulation. 2007;115:1051-1058.
-
- Mackman N.** *Triggers, targets and treatments for thrombosis.*
Nature. 2008;451:914-918. Review.
-
- Marroquin OC, Selzer F, Mulukutla SR, et al.** *A comparison of bare-metal and drug-eluting stents for off-label indications.*
N Engl J Med. 2008;358:342-352.
-
- Marzocchi A, Saia F, Piovaccari G, et al.** *Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.*
Circulation. 2007;115:3181-3188.
-
- Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE.** *Stent thrombosis in randomized clinical trials of drug-eluting stents.*
N Engl J Med. 2007;356:1020-1029.
-
- Mehta RH, Leon MB, Sketch MH Jr; ENDEAVOR II Continued Access Registry.** *The relation between clinical features, angiographic findings, and the target lesion revascularization rate in patients receiving the Endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: an analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III.*
Am J Cardiol. 2007;100:62M-70M.
-



-
- Melikian N, Wijns W.** *Drug-eluting stents: a critique.*
Heart. 2008;94:145-152. Review.
-
- Mintz GS, Weissman NJ.** *Intravascular ultrasound in the drug-eluting stent era.*
J Am Coll Cardiol. 2006;48:421-429.
-
- Miyazawa A, Ako J, Hongo Y, et al; ENDEAVOR III Investigators.** *Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III.*
Am Heart J. 2008;155:108-113.
-
- Morice MC, Colombo A, Meier B, et al; REALITY Trial Investigators.** *Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.*
JAMA. 2006;295:895-904.
-
- Morice MC, Serruys PW, Barragan P, et al.** *Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial.*
J Am Coll Cardiol. 2007;50:1299-1304.
-
- Ong AT, Daemen J, van Hout BA, et al.** *Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1- and 2-year follow-up: results from the RESEARCH Registry.*
Eur Heart J. 2006;27:2996-3003.
-
- Ormiston JA, Serruys PW, Regar E, et al.** *A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial.*
Lancet. 2008;371:899-907.
-
- Palmerini T, Marzocchi A, Marrozzini C, et al.** *Comparison between coronary angioplasty and coronary artery bypass surgery for the treatment of unprotected left main coronary artery stenosis (the Bologna Registry).*
Am J Cardiol. 2006;98:54-59.
-
- Park DW, Yun SC, Lee SW, et al.** *Long-term mortality after percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass surgery for the treatment of multivessel coronary artery disease.*
Circulation. 2008;117:2079-2086.
-
- Pfisterer M, Brunner-La Rocca HP, Buser PT, et al; BASKET-LATE Investigators.** *Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.*
J Am Coll Cardiol. 2006;48:2584-2591.
-
- Pinto DS, Stone GW, Ellis SG, et al; TAXUS-IV Investigators.** *Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial.*
J Am Coll Cardiol. 2006;48:32-36.
-
- Pinto Slottow TL, Waksman R.** *Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the endeavor zotarolimus-eluting coronary stent.*
Circulation. 2008;117:1603-1608.
-
- Pocock SJ, Lansky AJ, Mehran R, et al.** *Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials.*
J Am Coll Cardiol. 2008;51:23-32.
-

Bibliography of One Hundred Key Papers

- Price MJ, Endemann S, Gollapudi RR, et al.** *Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.*
Eur Heart J. 2008;29:992-1000.
-
- Reicher B, Poston RS, Mehra MR, et al.** *Simultaneous “hybrid” percutaneous coronary intervention and minimally invasive surgical bypass grafting: feasibility, safety, and clinical outcomes.*
Am Heart J. 2008;155:661-667.
-
- Rodriguez AE, Maree AO, Mieres J, et al.** *Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry.*
Eur Heart J. 2007;28:2118-2125.
-
- Ryan J, Cohen DJ.** *Are drug-eluting stents cost-effective? It depends on whom you ask.*
Circulation. 2006;114:1736-1743.
-
- Schömig A, Dibra A, Windecker S, et al.** *A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.*
J Am Coll Cardiol. 2007;50:1373-1380. Review.
-
- Serruys PW, Daemen J, Morice MC, et al; . ARTS II Investigators** *Three-year follow-up of the ARTS-II—Sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease.*
EuroInterv. 2007;3:450-459.
-
- Serruys PW, Sianos G, Abizaid A, et al.** *The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES).*
J Am Coll Cardiol. 2005;46:253-260.
-
- Seung KB, Park DW, Kim YH, et al.** *Stents versus coronary-artery bypass grafting for left main coronary artery disease.*
N Engl J Med. 2008;358:1781-1792.
-
- Sianos G, Papafaklis MI, Daemen J, et al.** *Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden.*
J Am Coll Cardiol. 2007;50:573-583.
-
- Siqueira DA, Abizaid AA, Costa J de R, et al.** *Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes.*
Eur Heart J. 2007;28:1304-1309.
-
- Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW.** *A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents.*
N Engl J Med. 2007;356:989-997.
-
- Spaulding C, Henry P, Teiger E, et al; TYPHOON Investigators.** *Sirolimus-eluting versus uncoated stents in acute myocardial infarction.*
N Engl J Med. 2006;355:1093-1104;
-
- Spertus JA, Kettelkamp R, Vance C, et al.** *Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.*
Circulation. 2006;113:2803-2809.
-



Bibliography of One Hundred Key Papers

-
- Steigen TK, Maeng M, Wiseth R, et al; Nordic PCI Study Group.** *Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study.* **Circulation.** 2006;114:1955-1961.
-
- Steinberg DH, Pinto Slottow TL, et al.** *Impact of in-stent restenosis on death and myocardial infarction.* **Am J Cardiol.** 2007;100:1109-1113.
-
- Stone GW, Ellis SG, Colombo A, et al.** *Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare-metal stent implantation.* **Circulation.** 2007;115:2842-2847.
-
- Stone GW, Ellis SG, O'Shaughnessy CD, et al; TAXUS V ISR Investigators.** *Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.* **JAMA.** 2006;295:1253-1263.
-
- Stone GW, Midei M, Newman W, Sanz M, et al; SPIRIT III Investigators.** *Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.* **JAMA.** 2008;299:1903-1913.
-
- Stone GW, Moses JW, Ellis SG, et al.** *Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.* **N Engl J Med.** 2007;356:998-1008.
-
- Svilaas T, Vlaar PJ, van der Horst IC, et al.** *Thrombus aspiration during primary percutaneous coronary intervention.* **N Engl J Med.** 2008;358:557-567.
-
- Taggart DP, Kaul S, Boden WE, et al.** *Revascularization for unprotected left main stem coronary artery stenosis: stenting or surgery.* **J Am Coll Cardiol.** 2008;51:885-892.
-
- Togni M, Eber S, Widmer J, et al.** *Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial.* **J Am Coll Cardiol.** 2007;50:1123-1131.
-
- Tu JV, Bowen J, Chiu M, et al.** *Effectiveness and safety of drug-eluting stents in Ontario.* **N Engl J Med.** 2007;357:1393-1402.
-
- Valgimigli M, Campo G, Arcozzi C, et al.** *Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study.* **J Am Coll Cardiol.** 2007;50:138-145.
-
- Valgimigli M, Campo G, Percoco G, et al; Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators.** *Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.* **JAMA.** 2008;299:1788-1799.
-
- Valgimigli M, van Mieghem CA, Ong AT, et al.** *Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH).* **Circulation.** 2005;111:1383-1389.
-

Bibliography of One Hundred Key Papers

- Van Beusekom HM, Saia F, Zindler JD, et al.** *Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus.*
Eur Heart J. 2007;28:974-979.
-
- Van der Hoeven BL, Liem SS, Jukema JW, et al.** *Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study.*
J Am Coll Cardiol. 2008;51:618-626.
-
- Van Mieghem CA, Cademartiri F, Mollet NR, et al.** *Multislice spiral computed tomography for the evaluation of stent patency after left main coronary artery stenting: a comparison with conventional coronary angiography and intravascular ultrasound.*
Circulation. 2006;114:645-653.
-
- Vermeersch P, Agostoni P, Verheye S, et al.** *Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.*
J Am Coll Cardiol. 2006;48:2423-2431.
-
- Vermeersch P, Agostoni P, Verheye S, et al; DELAYED RRISC (Death and Events at Long-term follow-up Analysis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators.** *Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial.*
J Am Coll Cardiol. 2007;50:261-267.
-
- Wessely R, Kastrati A, Mehilli J, Dibra A, Pache J, Schömig A.** *Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design.*
Eur Heart J. 2007;28:2720-2725.
-
- Williams DO, Abbott JD, Kip KE; DEScover Investigators.** *Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry.*
Circulation. 2006;114:2154-2162.
-
- Windecker S, Remondino A, Eberli FR, et al.** *Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.*
N Engl J Med. 2005;353:653-662.
-
- Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators.** *Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.*
Lancet. 2008;371:1353-1363.
-
- Yamaguchi T, Terashima M, Akasaka T, et al.** *Safety and feasibility of an intravascular optical coherence tomography image wire system in the clinical setting.*
Am J Cardiol. 2008;101:562-567.
-